Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan

Minako Iida, Takahiro Fukuda, Naoyuki Uchida, Makoto Murata, Nobuyuki Aotsuka, Kentaro Minagawa, Kazuteru Oohashi, Kentaro Fukushima, Tadakazu Kondo, Tetsuya Eto, Toshihiro Miyamoto, Yasuo Morishima, Tokiko Nagamura, Yoshiko Atsuta, Ritsuro Suzuki

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Our previous study of 301 patients who received hematopoietic stem cell transplantation (HSCT) from related donors demonstrated the efficacy of mycophenolate mofetil (MMF) for prophylaxis and treatment of graft-vs.-host disease (GVHD). In this study, we investigated the safety and efficacy of MMF in 716 adult patients who received unrelated HSCT. The incidences of Grade II-IV and III-IV acute GVHD in the prophylactic administration group were 38.3% and 14.3%, respectively. These rates were not statistically significant when evaluating the MMF dosage and graft source. The incidences of limited and extensive chronic GVHD were 16.6% and 11.1%, respectively. In the therapeutic administration group, 69.1% of the subjective symptoms for both acute and chronic GVHD improved. With respect to the adverse events, 75 infections and 50 cases of diarrhea were observed, and the frequency of these events increased with increasing MMF dose. The overall survival rate was 36.4% after a median follow-up period of three yr. This study shows that MMF is safe and effective for the prevention and treatment of GVHD in patients who have received HSCT from unrelated donors.

Original languageEnglish
Pages (from-to)980-989
Number of pages10
JournalClinical Transplantation
Volume28
Issue number9
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Mycophenolic Acid
Hematopoietic Stem Cell Transplantation
Japan
Transplants
Therapeutics
Unrelated Donors
Incidence
Diarrhea
Survival Rate
Tissue Donors
Safety
Infection

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. / Iida, Minako; Fukuda, Takahiro; Uchida, Naoyuki; Murata, Makoto; Aotsuka, Nobuyuki; Minagawa, Kentaro; Oohashi, Kazuteru; Fukushima, Kentaro; Kondo, Tadakazu; Eto, Tetsuya; Miyamoto, Toshihiro; Morishima, Yasuo; Nagamura, Tokiko; Atsuta, Yoshiko; Suzuki, Ritsuro.

In: Clinical Transplantation, Vol. 28, No. 9, 01.01.2014, p. 980-989.

Research output: Contribution to journalArticle

Iida, M, Fukuda, T, Uchida, N, Murata, M, Aotsuka, N, Minagawa, K, Oohashi, K, Fukushima, K, Kondo, T, Eto, T, Miyamoto, T, Morishima, Y, Nagamura, T, Atsuta, Y & Suzuki, R 2014, 'Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan', Clinical Transplantation, vol. 28, no. 9, pp. 980-989. https://doi.org/10.1111/ctr.12405
Iida, Minako ; Fukuda, Takahiro ; Uchida, Naoyuki ; Murata, Makoto ; Aotsuka, Nobuyuki ; Minagawa, Kentaro ; Oohashi, Kazuteru ; Fukushima, Kentaro ; Kondo, Tadakazu ; Eto, Tetsuya ; Miyamoto, Toshihiro ; Morishima, Yasuo ; Nagamura, Tokiko ; Atsuta, Yoshiko ; Suzuki, Ritsuro. / Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan. In: Clinical Transplantation. 2014 ; Vol. 28, No. 9. pp. 980-989.
@article{f21b68db6c5548f389b1cd92c11854a9,
title = "Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan",
abstract = "Our previous study of 301 patients who received hematopoietic stem cell transplantation (HSCT) from related donors demonstrated the efficacy of mycophenolate mofetil (MMF) for prophylaxis and treatment of graft-vs.-host disease (GVHD). In this study, we investigated the safety and efficacy of MMF in 716 adult patients who received unrelated HSCT. The incidences of Grade II-IV and III-IV acute GVHD in the prophylactic administration group were 38.3{\%} and 14.3{\%}, respectively. These rates were not statistically significant when evaluating the MMF dosage and graft source. The incidences of limited and extensive chronic GVHD were 16.6{\%} and 11.1{\%}, respectively. In the therapeutic administration group, 69.1{\%} of the subjective symptoms for both acute and chronic GVHD improved. With respect to the adverse events, 75 infections and 50 cases of diarrhea were observed, and the frequency of these events increased with increasing MMF dose. The overall survival rate was 36.4{\%} after a median follow-up period of three yr. This study shows that MMF is safe and effective for the prevention and treatment of GVHD in patients who have received HSCT from unrelated donors.",
author = "Minako Iida and Takahiro Fukuda and Naoyuki Uchida and Makoto Murata and Nobuyuki Aotsuka and Kentaro Minagawa and Kazuteru Oohashi and Kentaro Fukushima and Tadakazu Kondo and Tetsuya Eto and Toshihiro Miyamoto and Yasuo Morishima and Tokiko Nagamura and Yoshiko Atsuta and Ritsuro Suzuki",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/ctr.12405",
language = "English",
volume = "28",
pages = "980--989",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan

AU - Iida, Minako

AU - Fukuda, Takahiro

AU - Uchida, Naoyuki

AU - Murata, Makoto

AU - Aotsuka, Nobuyuki

AU - Minagawa, Kentaro

AU - Oohashi, Kazuteru

AU - Fukushima, Kentaro

AU - Kondo, Tadakazu

AU - Eto, Tetsuya

AU - Miyamoto, Toshihiro

AU - Morishima, Yasuo

AU - Nagamura, Tokiko

AU - Atsuta, Yoshiko

AU - Suzuki, Ritsuro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Our previous study of 301 patients who received hematopoietic stem cell transplantation (HSCT) from related donors demonstrated the efficacy of mycophenolate mofetil (MMF) for prophylaxis and treatment of graft-vs.-host disease (GVHD). In this study, we investigated the safety and efficacy of MMF in 716 adult patients who received unrelated HSCT. The incidences of Grade II-IV and III-IV acute GVHD in the prophylactic administration group were 38.3% and 14.3%, respectively. These rates were not statistically significant when evaluating the MMF dosage and graft source. The incidences of limited and extensive chronic GVHD were 16.6% and 11.1%, respectively. In the therapeutic administration group, 69.1% of the subjective symptoms for both acute and chronic GVHD improved. With respect to the adverse events, 75 infections and 50 cases of diarrhea were observed, and the frequency of these events increased with increasing MMF dose. The overall survival rate was 36.4% after a median follow-up period of three yr. This study shows that MMF is safe and effective for the prevention and treatment of GVHD in patients who have received HSCT from unrelated donors.

AB - Our previous study of 301 patients who received hematopoietic stem cell transplantation (HSCT) from related donors demonstrated the efficacy of mycophenolate mofetil (MMF) for prophylaxis and treatment of graft-vs.-host disease (GVHD). In this study, we investigated the safety and efficacy of MMF in 716 adult patients who received unrelated HSCT. The incidences of Grade II-IV and III-IV acute GVHD in the prophylactic administration group were 38.3% and 14.3%, respectively. These rates were not statistically significant when evaluating the MMF dosage and graft source. The incidences of limited and extensive chronic GVHD were 16.6% and 11.1%, respectively. In the therapeutic administration group, 69.1% of the subjective symptoms for both acute and chronic GVHD improved. With respect to the adverse events, 75 infections and 50 cases of diarrhea were observed, and the frequency of these events increased with increasing MMF dose. The overall survival rate was 36.4% after a median follow-up period of three yr. This study shows that MMF is safe and effective for the prevention and treatment of GVHD in patients who have received HSCT from unrelated donors.

UR - http://www.scopus.com/inward/record.url?scp=84908339074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908339074&partnerID=8YFLogxK

U2 - 10.1111/ctr.12405

DO - 10.1111/ctr.12405

M3 - Article

C2 - 24943923

AN - SCOPUS:84908339074

VL - 28

SP - 980

EP - 989

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 9

ER -